[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:peripheral-t-cell-lymphoma-not-otherwise-specified":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":80,"states":81},"Peripheral T-Cell Lymphoma, Not Otherwise Specified",11,10,[8,16,22,29,36,42,48,54,61,67,73],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04083495","CD30 CAR for Relapsed\u002FRefractory CD30+ T Cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:19:18.331180Z","2026-05-05T02:43:29.068613Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06630091","A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study",[12],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.073550Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06508463","Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma",[26],"Phase 1","2026-08-26T02:18:07.037408Z","2026-07-05T05:32:16.756962Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06724237","Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy",[33],"Phase 3","2026-08-26T02:18:27.904411Z","2026-05-13T02:55:06.567458Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06561048","Soquelitinib vs Standard of Care in Participants With Relapsed\u002FRefractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma",[33],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:28.359184Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT03017820","A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma",[26],"2026-08-26T02:19:05.360997Z","2026-06-16T05:54:07.906191Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05967416","Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma",[26],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:27.815843Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT04390737","Evaluate the Safety and Clinical Activity of HH2853",[58],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:26.959800Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:26.753431Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT04045470","A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma",[],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.124870Z",{"nct_id":74,"title":75,"phases":76,"status":77,"updated_at":78,"content_modified":79},"NCT07691450","Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma",[26],"NOT_YET_RECRUITING","2026-08-26T02:16:42.787115Z","2026-07-19T19:36:05.157190Z",[],[82,86,90,93,96,100],{"state":83,"count":84,"slug":85},"Minnesota",5,"minnesota",{"state":87,"count":88,"slug":89},"Arizona",4,"arizona",{"state":91,"count":88,"slug":92},"California","california",{"state":94,"count":88,"slug":95},"Texas","texas",{"state":97,"count":98,"slug":99},"Florida",3,"florida",{"state":101,"count":98,"slug":102},"North Carolina","north-carolina"]